Man Group
FATE icon

Man Group’s Fate Therapeutics FATE Stock Holding History

Man Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$475K Sell
176,107
-253,966
-59% -$470K ﹤0.01% 2074
2026
Q1 		$516K Buy
430,073
+168,901
+65% +$206K ﹤0.01% 2074
2025
Q4 		$257K Buy
261,172
+41,514
+19% +$49.9K ﹤0.01% 2069
2025
Q3 		$277K Buy
+219,658
New +$237K ﹤0.01% 2030
2024
Q1 		– Sell
-252,676
Closed -$945K – 2159
2023
Q4 		$945K Buy
+252,676
New +$596K ﹤0.01% 1467
2023
Q3 		– Sell
-173,940
Closed -$576K – 1530
2023
Q2 		$828K Buy
+173,940
New +$960K ﹤0.01% 1448
2023
Q1 		– Sell
-93,837
Closed -$566K – 1583
2022
Q4 		$947K Buy
93,837
+76,537
+442% +$1.44M ﹤0.01% 1333
2022
Q3 		$388K Buy
+17,300
New +$500K ﹤0.01% 1595
2022
Q1 		– Sell
-12,430
Closed -$727K – 2221
2021
Q4 		$727K Buy
+12,430
New +$705K ﹤0.01% 1421
2021
Q2 		– Sell
-6,212
Closed -$512K – 1996
2021
Q1 		$512K Sell
6,212
-73,111
-92% -$7.01M ﹤0.01% 1471
2020
Q4 		$7.21M Sell
79,323
-25,977
-25% -$1.61M 0.03% 594
2020
Q3 		$4.21M Buy
105,300
+78,133
+288% +$2.73M 0.02% 899
2020
Q2 		$932K Buy
+27,167
New +$810K ﹤0.01% 1295

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Man Group's FATE Position: Q2 2026 in Review

Man Group reduced its Fate Therapeutics (FATE) stake by 59% in Q2 2026, selling an estimated $470K and leaving 176,107 shares worth $475K. The position accounts for ﹤0.01% of the portfolio, ranked #2074.

Man Group first reported a position in FATE in Q2 2020 and has held it in 13 quarters since. The position peaked at $7.21M in Q4 2020. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Man Group held 176,107 shares of Fate Therapeutics worth $475K as of Q2 2026.
  • Man Group sold 253,966 Fate Therapeutics shares in Q2 2026, an estimated $470K.
  • Fate Therapeutics made up ﹤0.01% of Man Group's portfolio in Q2 2026, its #2074 holding.
  • Man Group first reported a position in Fate Therapeutics in Q2 2020 and has held it in 13 quarters since.
  • Man Group's Fate Therapeutics position peaked at $7.21M in Q4 2020.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.